LENZ THERAPEUTICS, INC. Increase (Decrease) in Employee Related Liabilities
LENZ THERAPEUTICS, INC. (LENZ) reported Increase (Decrease) in Employee Related Liabilities of -$2.27 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2024-02-27
- LENZ THERAPEUTICS, INC. increase (decrease) in employee related liabilities for the quarter ending 2023-12-31 was -$365.00K, a 180.57% decline year-over-year.
- LENZ THERAPEUTICS, INC. increase (decrease) in employee related liabilities for the quarter ending 2023-09-30 was -$369.00K, a 131.67% decline year-over-year.
- LENZ THERAPEUTICS, INC. increase (decrease) in employee related liabilities for the quarter ending 2023-06-30 was $954.00K, a 17.62% decline year-over-year.
- LENZ THERAPEUTICS, INC. increase (decrease) in employee related liabilities for the quarter ending 2023-03-31 was -$2.48M.
- LENZ THERAPEUTICS, INC. increase (decrease) in employee related liabilities for fiscal 2023 was -$2.27M, a 304.05% decline from fiscal 2022.
- LENZ THERAPEUTICS, INC. increase (decrease) in employee related liabilities for fiscal 2022 was $1.11M, a 50.07% decline from fiscal 2021.
- LENZ THERAPEUTICS, INC. increase (decrease) in employee related liabilities for fiscal 2021 was $2.22M, a 377.04% increase from fiscal 2020.
- LENZ THERAPEUTICS, INC. increase (decrease) in employee related liabilities for fiscal 2020 was $466.00K.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$734.00K derived: sum of 2 quarters · filed 2024-02-27 | $220.00K derived: sum of 3 quarters · filed 2024-02-27 | -$2.27M 10-K · filed 2024-02-27 |
| 2023-09-30 | -$369.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $585.00K derived: sum of 2 quarters · filed 2023-11-13 | -$1.90M 10-Q · filed 2023-11-13 | -$1.45M derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-06-30 | $954.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$1.53M 10-Q · filed 2023-08-14 | -$1.08M derived: sum of 3 quarters · filed 2024-02-27 | $87.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-03-31 | -$2.48M 10-Q · filed 2023-05-11 | -$2.03M derived: sum of 2 quarters · filed 2024-02-27 | -$867.00K derived: sum of 3 quarters · filed 2024-02-27 | $291.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-12-31 | $453.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.62M derived: sum of 2 quarters · filed 2024-02-27 | $2.78M derived: sum of 3 quarters · filed 2024-02-27 | $1.11M 10-K · filed 2024-02-27 |
| 2022-09-30 | $1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $2.32M derived: sum of 2 quarters · filed 2023-11-13 | $657.00K 10-Q · filed 2023-11-13 | $1.69M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$508.00K 10-Q · filed 2023-08-14 | $522.00K derived: sum of 3 quarters · filed 2023-08-14 | $1.46M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$1.67M 10-Q · filed 2023-05-11 | -$636.00K derived: sum of 2 quarters · filed 2023-05-11 | $300.00K derived: sum of 3 quarters · filed 2023-05-11 | $736.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $1.97M derived: sum of 2 quarters · filed 2023-03-20 | $2.40M derived: sum of 3 quarters · filed 2023-03-20 | $2.22M 10-K · filed 2023-03-20 |
| 2021-09-30 | $936.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.37M derived: sum of 2 quarters · filed 2022-11-09 | $1.19M 10-Q · filed 2022-11-09 | $1.49M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $436.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $257.00K 10-Q · filed 2022-08-11 | $553.00K derived: sum of 3 quarters · filed 2022-08-11 | $670.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$179.00K 10-Q · filed 2022-05-12 | $117.00K derived: sum of 2 quarters · filed 2022-05-12 | $234.00K derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $296.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $413.00K derived: sum of 2 quarters · filed 2022-03-21 | $466.00K 10-K · filed 2022-03-21 | |
| 2020-09-30 | $117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $170.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $53.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |